Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (341-350 of 384) with videos related to

Pageof 39
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 25, 2011
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remissionSherif S Farag, Kati Maharry, Mei-Jie Zhang, et al.
Blood|June 27, 2012
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemiaRobert E Gallagher, Barry K Moser, Janis Racevskis, et al.
Blood|June 17, 2022
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trialStéphane de Botton, Pau Montesinos, Andre C Schuh, et al.
Blood|July 27, 2010
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySusan P Whitman, Kati Maharry, Michael D Radmacher, et al.
Leukemia|June 5, 2021
Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTRMatthew J Wieduwilt, Wendy Stock, Anjali Advani, et al.
Cancer Cell|October 20, 2012
Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemiaXi Jiang, Hao Huang, Zejuan Li, et al.
Nature Communications|April 27, 2016
miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemiaXi Jiang, Chao Hu, Stephen Arnovitz, et al.
Blood|April 25, 2012
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemiaAnn-Kathrin Eisfeld, Guido Marcucci, Kati Maharry, et al.
JAMA Oncology|November 12, 2020
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical TrialEhab Atallah, Charles A Schiffer, Jerald P Radich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE StudyDavid A Sallman, Guillermo Garcia-Manero, Naval Daver, et al.
Pageof 39

Showing results (341-350 of 384) with videos related to

Sort By:
Pageof 39
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 25, 2011
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remissionSherif S Farag, Kati Maharry, Mei-Jie Zhang, et al.
Blood|June 27, 2012
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemiaRobert E Gallagher, Barry K Moser, Janis Racevskis, et al.
Blood|June 17, 2022
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trialStéphane de Botton, Pau Montesinos, Andre C Schuh, et al.
Blood|July 27, 2010
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySusan P Whitman, Kati Maharry, Michael D Radmacher, et al.
Leukemia|June 5, 2021
Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTRMatthew J Wieduwilt, Wendy Stock, Anjali Advani, et al.
Cancer Cell|October 20, 2012
Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemiaXi Jiang, Hao Huang, Zejuan Li, et al.
Nature Communications|April 27, 2016
miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemiaXi Jiang, Chao Hu, Stephen Arnovitz, et al.
Blood|April 25, 2012
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemiaAnn-Kathrin Eisfeld, Guido Marcucci, Kati Maharry, et al.
JAMA Oncology|November 12, 2020
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical TrialEhab Atallah, Charles A Schiffer, Jerald P Radich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE StudyDavid A Sallman, Guillermo Garcia-Manero, Naval Daver, et al.
Pageof 39